INTRODUCTION {#s1}
============

Rectal cancer is associated with substantial morbidity and mortality, especially in elder patients and those with co-morbidities. Outcome after these surgeries depends both on modifiable factors, such as perioperative medical care, and on physiological tolerance of surgical trauma. Over the last two decades, we have seen a continuous improvement of the quality of laparoscopic surgery in rectal cancer, especially in specialized centers with longstanding experience and high annual volumes. Several studies that compared laparoscopic and conventional open resection for rectal cancer show no difference with respect to local recurrence or overall and disease-free survival after 3, 5 \[[@R1], [@R2]\] even 10 years \[[@R3]\], respectively. More recently, long-term data including the MRC CR07 \[[@R4]\], MRC CLASICC trial, Comparison of Open versus laparoscopic surgery for mid or low Rectal cancer After Neoadjuvant chemoradiotherapy (COREAN) trial \[[@R5]\], the Colorectal cancer laparoscopic or Open Resection (COLOR II) trial \[[@R6]\] have released long-term survival rates. Though some of the randomized control trials have included patients with elevated preoperative risk (American Society of Anesthesiologists classification 3 and 4), these patients were generally recruited to clinical trials less often than younger patients and therefore are under-represented in publications about cancer treatment \[[@R7]\]. Because of this heterogeneous, can these recommendations from major studies, such as laparoscopic rectal operations are safe and sound, be extrapolated to the fragile subset of patients with more comorbidity or do they need to be modified? The aim of this study is to analysis the survival and outcomes in patients with rectal cancer associated with high operative risk in conventional open rectal resection group (OpS) and laparoscopic rectal resection group (LaPS).

MATERIALS AND METHODS {#s2}
=====================

Patients {#s2_1}
--------

This study included all 1477 consecutive patients undergoing radical surgical resection for rectal cancer in a tertiary referral teaching hospital - Shanghai Ruijin Hospital between September 2007 and Nov 2011. 220 patients were considered with high operative risk. Patients were admitted to Gastrointestinal Surgical Centre or Minimally Invasive Surgical Centre. Both centers belong to Department of General Surgery. The operative conditions, anesthesia management as well as perioperative management were at the same level. Both surgical teams had the same operative quality of rectal cancer. Emergency protectomy was excluded.

Diagnoses and tumor stage {#s2_2}
-------------------------

The diagnoses were made preoperatively and then confirmed by postoperative pathology. The tumor node metastasis (TNM) staging of colon and rectal cancer system (American Joint Committee on Cancer Manual, 7th edition) was used. The criteria for neoadjuvant radiochemotherapy were patients with rectal cancer of the lower and middle third of the rectum and suspected T3 or T4 tumors and patients with pathological lymph nodes as demonstrated by CT or MRI-scan.

Surgical procedures and quality control {#s2_3}
---------------------------------------

Patient demographics were extracted routinely by trained registrars from the hospital records. Patients were assigned preoperatively to the laparoscopic or open approach based on clinical criteria and imaging, including chest radiograph, abdominal computed tomography, and colonoscopy etc. Patients' preference had also been considered. Conversion cases were deemed necessary remained in the laparoscopic surgery group for all outcomes by intention-to-treat analysis. The preoperative preparation and the techniques of the procedures were described previously. With our experience from open total mesorectal excision, laparoscopic surgery was performed according to the same oncologic principles \[[@R8], [@R9]\]. Briefly, laparoscopic surgery was done with five trocars, the rectum was mobilized with monopolar cautery or an ultrasonic scalpel, dissecting between the visceral and parietal pelvic fascia without injuring the hypogastric nerves. Laparoscopic and open procedures were performed by four senior surgeons with their specialist team from the division of Gastrointestinal Surgery or division of Minimally Invasive Surgery in Ruijin Hospital. In the LapS group, surgery was performed by a systemic team of surgeons with abundant experience and expertise in conventional colorectal surgery and laparoscopic skills. In the OpS group, another fixed group of experienced surgeons specializing in colorectal surgery executed the surgery. \[[@R9]\]

Statistical methods {#s2_4}
-------------------

Analyses were performed with Stat View 5.0 for Windows (SAS Institute Inc., Cary, NC, USA). The Х2 test or Fisher\'s exact test was applied to analyze the categorical variables. The results were subjected to a nonparametric Mann-Whitney U test. A Student\'s t-test was also used to analyze the intragroup differences. The Kaplan-Meier method was used to analyze the overall survival of patients; the log-rank test was used to compare patient survival between groups. Cox-regression model was used for multivariate analysis. Logistic regression was used to analyze the correlation of Cr-POSSUM and Dindo-Demartines-Clavien Classification. P \< 0.05 was regarded as statistically significant.

Propensity score matching {#s2_5}
-------------------------

Propensity score matching was applied to reduce the effect of treatment selection bias and potential confounding effect, thereby creating a quasi-randomized experiment. This matching is done using a generalized SAS macro that matches Ops to LapS at a 1:1 ratio, using an algorithm to maximize the number of propensity score match. Patients were selected based on this score calculating for baseline characteristics; that is age, gender, tumor size, tumor location, tumor stage, Cr-possum value and radiochemotherapy at baseline in patients.

Risk evaluation {#s2_6}
---------------

Patients with a predicted Colorectal Physiologic and Operative Severity Score for the enumeration of Mortality and Morbidity (Cr-POSSUM) ≥5% OR criteria below \[[@R10]\] were managed as 'high operative risk': Aged \> 60 yearsPLUS undergoing re-do surgeryOR have acute or chronic renal impairment (sCr \> 130 μmol/L)OR have diabetes mellitusOR are strongly suspected clinically to have any significant risk factor for the cardiac or respiratory disease. (e. g. chronic obstructive pulmonary disease, history of ischemic heart disease, congestive heart failure, arrhythmias, angina pectoris, or cardiac risk index \> 12 etc.)have shock of any cause, any age group.Cr-POSSUM scores were calculated for each patient retrospectively from their medical records. The calculating software is freely available on the internet ([http://www.riskprediction.org.uk/index-cr.php](http://www.riskprediction.org.uk/index-cr.php,), Risk Prediction in Surgery)

RESULTS {#s3}
=======

There was no significant difference between each group concerning the age (69±11.2 vs 68±12.1 years old, p = 0.5907). The Body mass index (BMI) were 28.1kg/m2 and 27.9kg/m2 (p = 0.437). The tumor size was 3.60±1.58cm and 3.57±0.84cm, respectively (p = 0.916), and located in 6.18cm and 6.36cm from the anal verge. The tumor stage, postoperative radiochemotherapy, circumferential resection margin ( \< 2mm) positivity (LapS 1of 66 \[2%\] vs OpS 1 of 66 \[2%\]), distal margin, macroscopic completeness of the resection (incomplete rate: LapS 9% vs OpS 10%), locoregional recurrence rate (LapS 4of 66 \[6%\] vs OpS 5 of 66 \[8%\]) did not differ between laparoscopic and open surgery groups.

Operative risk {#s3_1}
--------------

The distribution of ages and Cr-POSSUM were showed in Table [1](#T1){ref-type="table"}. 37 patients (56%) in OpS group were with a Cr-POSSUM score ≥10%, 13 patients (20% in total) of which were with a Cr-POSSUM score ≥20%; while in LapS group, the amount of patients with score above 10% and 20% were 30 patients (45%) and 15 patients (22%), respectively. Concerning the 4 patients whose scores were below 5% in OpS group, three patients were older than 50 years old with pulmonary dysfunction, one patient was 59 years old undergoing re-do surgery. In LapS group, three in five patients were beyond 50 years old combining with pulmonary dysfunction; one was with chronic renal impairment; one patient experienced re-do surgery. In total, there were 3 and 2 patients in each group underwent re-do surgery, eighteen and twelve patients suffered from acute or chronic renal impairment, thirteen and eight patients were suffering from diabetes mellitus in OpS and LapS group, respectively. 50%, 50% patients in OpS group and 32%, 33% patients were suffering from Cardiac and respiratory disease, respectively. 3% patients in the open surgery group have cerebrovascular disease. Generally speaking, there was no significant difference between the two groups in preoperative risk.

###### The patient demographics and histopathological tumor assessment

  ----------------------------------------------------------------------------------------------------------
  Clinical or pathologic feature            OpS (*n*= 66)   LapS (*n*= 66)   *P*-value   95%CI            
  ----------------------------------------- --------------- ---------------- ----------- ---------------- --
  **Sex ratio ( Male: Female)**             45:22           46:21            0.85        -0.1794-0.1491   

  **Age (years)**                           69±11.2         68±12.1          0.59        -2.984-5.196     

  **Body mass index (kg/m2)**               28.1            27.9             0.44                         

  **pTumor stage (AJCC)**                                                                                 

  I                                         18              17                                            

  IIA                                       17              10                                            

  IIIB                                      6               12                                            

  IIIA                                      3               5                0.85        -0.2982-0.3588   

  IIIB                                      10              12                                            

  IIIC                                      4               7                                             

  IV                                        8               3                                             

  **Lymph node metastasis**                                                                               

  N0                                        42              40               0.81                         

  N1                                        15              17                                            

  N≥2                                       9               9                                             

  **Tumor size (diameter, cm)**             3.60±1.58       3.57±0.84        0.92        -0.3812-0.4239   

  **Tumor location from anal verge (cm)**   6.18±1.94       6.36±2.06        0.54        -0.5259-0.9978   

  Low-rectal (0∼5cm)                        23              35                                            

  Mid-rectal (6∼10cm)                       40              26                                            

  Upper-rectal (\>10cm)                     3               5                                             

  **Type of surgery**                                                                                     

  APR                                       44              49                                            

  LAR                                       18              15               0.28                         

  Others                                    4               2                                             

  **Chemo-and/or radiotherapy**             23              26               0.61        -0.2204-0.1294   

  **Stoma formed**                                                                                        

  No                                        23              21                                            

  Ileostomy                                 20              29               0.58                         

  Colostomy                                 23              16                                            

  **Resection margin**\                     65              65                                            
  R0                                                                                                      

  R1                                        1               1                \--                          

  **Total mesorectal excision**                                                                           

  Complete                                  46              38                                            

  Nearly complete                           11              17               0.52                         

  Unknown                                   3               4                                             

  Incomplete                                6               7                                             
  ----------------------------------------------------------------------------------------------------------

Postoperative complications and outcomes {#s3_2}
----------------------------------------

The postoperative complications included surgical complications as well as general complications. Surgical complications contain anastomotic leakage \[[@R11]\], ileus, intra-abdominal abscess, urological or perineal wound complications, fistula, hemorrhage and deep vein thrombosis (Table [2](#T2){ref-type="table"}). And there were no significant differences between two groups except that laparoscopic group has a significant lower wound complication rate (2 vs 9). General complications include cardiac, respiratory, neurological and renal complications, Ascites etc. Cardiac complications happened in 4 and 3 patients respectively in OpS and LapS groups, containing postoperative heart failure, arrhythmia, angina and ischemic heart diseases, while, the number of patients in the laparoscopic group with respiratory complications was significantly lower (p = 0.03). Notably, the total complication rate between conventional open rectal resection (71 %) and laparoscopic surgery (41%) showed a significant difference (p = 0.0005). 2 cases (3%) in the LapS group were converted to open surgery in the present study.

###### Preoperative risk, postoperative complications and other outcomes

  Clinical or pathologic feature                                                                 OpS (*n*=66)   LapS (*n*=66)   *P*-value
  ---------------------------------------------------------------------------------------------- -------------- --------------- -----------
  **Preoperative risk**                                                                                                         
  **Cr-possum Score**                                                                                                           
  ∼ 10 percent                                                                                   29             36              
  10 ∼ 20 percent                                                                                24             15              0.65
  20∼ percent                                                                                    13             15              
  Undergoing re-do surgery                                                                       3              2               
  Acute or chronic renal impairment                                                              18             12              0.30
  Diabetes                                                                                       13             8               0.34
  Cardiac disease                                                                                33             21              0.051
  Respiratory disease                                                                            33             22              0.08
  Cerebrovascular disease                                                                        2              1               \-
  **Dindo-Demartines-Clavien Classification**                                                                                   
  Dindo 1                                                                                        33             41              
  Dindo 2                                                                                        24             9               0.92
  Dindo 3                                                                                        7              14              
  Dindo 4                                                                                        2              2               
  **Surgical complications**                                                                                                    
  Anastomotic leakage                                                                            5              6               \-
  Prolong ileus                                                                                  1              1               \-
  Intra-abdominal abscess                                                                        2              1               \-
  Urological complication                                                                        6              5               \-
  (transurethrale catheter-related problem, urinary tract infection/retension, ureter leakage)                                  
  Perineal wound complication                                                                    9              2               **0.03**
  (wound dehiscence, wound infections, wound necrosis, abscess or delayed wound healing)                                        
  perforation                                                                                    1              1               \-
  Gastrointestinal haemorrhage                                                                   2              3               \-
  Rectal stump abscess                                                                           4              1               0.37
  DVT                                                                                            0              1               \-
  **General complications**                                                                                                     
  Cardiac complication                                                                           4              3               \-
  Respiratory complication                                                                       10             2               **0.03**
  Neurological symptoms                                                                          1              0               \-
  Renal complication                                                                             3              0               0.24
  Ascites                                                                                        0              1               \-
  **Return to normal bowel function**                                                            5.5            4.0             
  **30-day mortality**                                                                           1              0               \-

Cr-POSSUM=Colorectal Physiologic and Operative Severity Score for the enumeration of Mortality and Morbidity. DVT, deep vein thrombosis

The correlation analysis of Cr-POSSUM and dindo-demartines-clavien classification {#s3_3}
---------------------------------------------------------------------------------

There is no significant difference between laparoscopic surgery and conventional surgical procedure in the distribution of Dindo-Demartines-Clavien Classification (p = 0.92). There is a significant positive correlation between open surgery and the Dindo-Demartines-Clavien Classification (Estimate = 0.7495, p= 0.02, 95%CI 1.102∼4.062). In addition, Cr-POSSUM is positively correlated with Dindo-Demartines-Clavien Classification (Estimate = 0.0458, p = 0.01, 95%CI 1.010∼1.085).

5-year overall survival, disease-free survival and disease-specific survival rates of different tumor stages and Cr-POSSUM score sub-groups {#s3_4}
-------------------------------------------------------------------------------------------------------------------------------------------

The median follow-up is 49.5 months. Using Log-rank analysis, no difference could be found between patients undergoing laparoscopic and open rectal resection in stage I∼II (p = 0.13, HR 0.5565, 95%CI 0.26-1.19), whereas the overall survival rate was statistically significantly higher in LapS group with stage III-IV tumor (p \< 0.0001, HR 0.70, 95%CI 0.27-1.79) Figure [1](#F1){ref-type="fig"}. We further used Cox regression to analyze the 132 patients; it also showed patients undergoing laparoscopic rectal resection had a better overall survival rate.

![5-year overall survival rates of Different Tumor Stages\
After Log-rank analysis, no difference could be found between patients undergoing laparoscopic and open rectal resection in stage I∼II (*p* = 0.13, HR 0.5565, 95%CI 0.26-1.19, Figure[1A](#F1){ref-type="fig"}), whereas the overall survival rate was statistically significantly higher in LapS group with stage III-IV tumor (*p* \< 0.0001, HR 0.70, 95%CI 0.27-1.79, Figure[1B](#F1){ref-type="fig"})](oncotarget-08-25679-g001){#F1}

The 5- year overall survival curves of patients in different Cr-POSSUM score sub-groups are shown in Figure [2D](#F2){ref-type="fig"}, [2E](#F2){ref-type="fig"}, [2F](#F2){ref-type="fig"}. The actuarial survivals of the laparoscopic and open groups with Cr-POSSUM valuing 10∼20% was without significantly different (p = 0.12, HR 2.02, 95%CI 0.83-4.90), so was for patients with Cr-POSSUM below 10% (p = 0.46) or above 20% (p = 0.64). The 5-year disease-free survival and disease specific survival are showed in Table [3](#T3){ref-type="table"}.

![Overall survival rates of patients with preoperative diseases or patients in different Cr-POSSUM score sub-groups\
**A**.-**C**., the overall survival rates of patients with cardiovascular, pulmonary and renal diseases. **D**.- **F**., The 5- year survival curves of patients in different Cr-POSSUM score sub-groups.](oncotarget-08-25679-g002){#F2}

###### Disease free survival, disease specific survival and overall survival

  Subgroup                                                               5-year survival    HR(95%CI)          *p*
  -------------------------------------- ----------------------- ------- ------------------ ------------------ ----------
  **Stage I∼II**                         Disease free survival   LapS    76.7%              0.58(0.28∼1.19)    0.14
                                         OpS                     89.1%                                         
  Disease specific survival              LapS                    74.1%   0.63(0.29∼1.36)    0.24               
                                         OpS                     88.6%                                         
  **Stage III∼IV**                       Disease free survival   LapS    60%                5.14(2.27∼11.68)   \<0.0001
                                         OpS                     38.4%                                         
  Disease specific survival              LapS                    62.1%   5.57(2.42∼12.81)   \<0.0001           
                                         OpS                     38.4%                                         
  **Preoperative respiratory disease**   Disease free survival   LapS    82.5%              0.40(0.18∼0.87)    0.02
                                         OpS                     64.6%                                         
  Disease specific survival              LapS                    86.4%   0.45(.020∼1.04)    0.047              
                                         OpS                     73.3%                                         
  **Preoperative renal disease**         Disease free survival   LapS    80.9%              0.41(0.15∼1.12)    0.049
                                         OpS                     59.9%                                         
  Disease specific survival              LapS                    81.9%   0.38(0.13∼1.15)    0.06               
                                         OpS                     61.6%                                         
  **Preoperative cardiac disease**       Disease free survival   LapS    71.9%              0.98(0.41∼2.37)    0.98
                                         OpS                     75.6%                                         
  Disease specific survival              LapS                    75.2%   0.81(0.32∼2.09)    0.68               
                                         OpS                     76.9%                                         
  **Cr-POSSUM\<10**                      Disease free survival   LapS    84.2%              0.68(0.27∼1.70)    0.40
                                         OpS                     89.1%                                         
  Disease specific survival              LapS                    84.2%   2.34(1.08∼5.07)    0.43               
                                         OpS                     82.9%                                         
  **Cr-POSSUM 10∼20**                    Disease free survival   LapS    73.8%              1.39(0.48∼4.01)    0.54
                                         OpS                     66.5%                                         
  Disease specific survival              LapS                    73.8%   1.28(0.43∼3.78)    0.66               
                                         OpS                     68.8%                                         
  **Cr-POSSUM \>20**                     Disease free survival   LapS    63.6%              1.44(0.54∼3.82)    0.46
                                         OpS                     61.1%                                         
  Disease specific survival              LapS                    72.5%   2.49(0.81∼7.64)    0.11               
                                         OpS                     57.6%                                         
  **\>75**                               Disease free survival   LapS    64.4%              0.89(0.42∼1.89)    0.76
                                         OpS                     60.7%                                         
  Disease specific survival              LapS                    69.4%   0.66(0.29∼1.42)    0.32               
                                         OpS                     59.1%                                         
  **\<75**                               Disease free survival   LapS    62.9%              0.79(0.36∼1.72)    0.55
                                         OpS                     60.8%                                         
  Disease specific survival              LapS                    62.9%   0.79(0.36∼1.72)    0.55               
                                         OpS                     60.8%                                         

Overall survival, disease-free survival and disease-specific survival rates of patients with preoperative cardiac, renal or respiratory diseases {#s3_5}
------------------------------------------------------------------------------------------------------------------------------------------------

The overall survival rates of patients with cardiovascular, pulmonary and renal diseases are shown in Figure [2A](#F2){ref-type="fig"}, [2B](#F2){ref-type="fig"}, [2C](#F2){ref-type="fig"}. In patients with the preoperative pulmonary disease, the 5-year overall survival rates of all stages and every different stage in these two groups were significantly different (p = 0.03 \[OS\], p = 0.02 \[DFS\]), while in patients with cardiovascular disease, the 5-year overall survivals were not significantly different (p = 0.9). For patients with the preoperative renal disease, the 5-year overall survival rates benefit from laparoscopic surgery with a significant difference. (p = 0.049), however, the disease-specific survival was not significantly different.

Furthermore, although people older than 75 years account for only 5∼10% of the overall population in developed countries and some developing countries, 35∼45% of patients with rectal cancer are in this age group. This proportion may increase in the future because of demographics of an aging population, and increases in life expectancy \[[@R12]\]. Thus, we separated the patients into two sub-groups (∼75, \> 75) by age (LapS 23 of 66 \[35 %\] \> 75y, OpS 26 of 66 \[39%\] \> 75y). The overall survival rate (Figure [3](#F3){ref-type="fig"}), disease-free survival rate, disease specific survival rate and the complication rate (not show) did not differ significantly in each group.

![The overall survival rates in age sub-groups (∼75, \> 75)](oncotarget-08-25679-g003){#F3}

DISCUSSION {#s4}
==========

Recently, the continual innovations of surgical approach are a major step towards the idea of personalized medicine, we should notice that it is still controversial about the treatment strategy for elderly patients with rectal tumor and those with elevated operative risk. Especially for patients with elevated operative risk, patients are most vulnerable when their pre-existing comorbidities make them susceptible to perioperative risk \[[@R13], [@R14], [@R15]\].

The COREAN trial demonstrated similar disease-free survival (Lap79.2% vs Open 72.5%) and overall survival rates (Lap 91.7% vs Open 90.4%). The 3-year disease-free survival rate (Lap74.8% vs Open 70.8%) and overall survival rates were similar between both approaches in COLOR II trial as well. More recently, American College of Surgeons Oncology Group \[ACOSOG\] Z6051 trial \[[@R16]\] and Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial \[AlaCaRT\] \[[@R17]\] investigated the non-inferiority of minimally invasive compared with open pelvic dissection for rectal cancer patients. The results suggest that a laparoscopic resection may not be oncologically justified in many patients requiring protectomy for rectal cancer. However, it was also reported that the follow-up studies to the ACOSOG Z6051 and ALaCaRT trials may show that long-term oncologic outcome are not compromised by a laparoscopic approach and slightly favorable outcomes might be seen as demonstrated by the COREAN and COLOR II trials. Other randomized trials and systematic reviews have also reported that laparoscopic and open proctectomy have similar oncological outcomes \[[@R18]\].However, little solid evidence exists in support of laparoscopic or open proctectomy for patients with high operative risk, although some literature showed that perioperative morbidity did not differ between two groups (Table [4](#T4){ref-type="table"}).

###### Recent comparative series in advanced rectal cancer

  -----------------------------------------------------------------------------------------------------------
  Reference                   Year   Lap: Open   Follow up        Stage   Survival                *P* value
  --------------------------- ------ ----------- ---------------- ------- ----------------------- -----------
  **Park *et al***            2009   170:374     36m (2-75)       1-3     3-year DFS lap 77.5%    0.29

                                                                              Open 82.6%          

  **Laurent *et al***         2009   238:233     52m(1-151)       1-3     5-year DFS lap 82%      NS

                                                                              Open 79%            

                                                                  3       5-year DFS lap ∼69%     NS

                                                                              Open ∼69%           

                                                                  3       5-year OS lap ∼72%      0.02

                                                                              Open ∼52%           

  **Law *et al***             2009   111:310     34m              3       5-year OS lap 56.6%     0.33

                                                                              Open 50%            

  **Li *et al***              2011   113:123     74.8m            3       5-year OS lap 66.7%     0.85

                                                                              Open 70.3%          

                                                                  1-3     5-year OS lap 77.9%     0.91

                                                                              Open 78.9%          

  **Liang *et al***           2011   69:174      Until 3 year     1-3     3-year OS               NS

  **Baik *et al***            2011   54:108      Until 5 year     3       5-year OS lap 91.7%     0.30

                                                                              Open 77.2%          

                                                                  3       5-year DFS lap ∼58.8%   0.63

                                                                              Open ∼51.5%         

  **Law *et al***             2012   814:1197    40.3m            3       5-year OS lap ∼58%      0.18

                                                                              Open ∼48%           

  **Park*et al***             2013   404:404     Until 3 years    1-3     5-year OS lap 82.1%     0.44

                                                                              Open 81.3%          

                                                                  3       5-year OS lap ∼70%      0.26

                                                                              Open ∼73%           

                                                                  3       5-year DFS lap ∼69%     0.18

                                                                              Open ∼59%           

  **Asoglu *et al***          2013   513:0       31m(7-64)        3       5-year OS lap ∼70%      \-

  **Good *et al***^30^        2013   130:0       40m              3       5-year OS lap 75.6%     \-

                                                                  4       5-year OS lap 53.8%     \-

  **Ng SS *et al***           2014   136:142     Until 10 years   1-3     10-year OS lap ∼58%     

                                                                              Open ∼48%           

                                                                  3       10-year RR lap 25.8%    0.08

                                                                              Open 43.2%          

  **Reibetanz *et al***^29^   2014   170:170     48m vs 46m       1-3     3-year OS               NS

  **Bonjer et al**\           2015   699:345     Until 3 year     1-3     3-year OS lap 86.7%     NS
  **( COLORII )**                                                                                 

      Open 83.6%                                                                                  

    DFS  lap 74.8%            NS                                                                  

      Open 70.8%                                                                                  

    RR  lap 5%                NS                                                                  

      Open 5%                                                                                     

  **Jeong et al**\            2015   170:170     Until 3 year     1-4     3-year OS lap 91.7%     NS
  **(COREAN)**                                                                                    

      Open 90.4%                                                                                  

    DFS  lap 79.2%            NS                                                                  

      Open 72.2%                                                                                  
  -----------------------------------------------------------------------------------------------------------

OS, overall survival; DFS, disease free survival; RR, recurrence rate

It is well accepted that laparoscopic approach is equivalent in the treatment of rectal cancer and shows advantages of shorter hospitalization and faster recovery, lower blood loss and lower complications rates \[[@R19]\], especially in patients with low rectal cancer \[[@R20], [@R21], [@R22]\].

Pulmonary comorbidities have been considered as an independent predictor of poor outcome in patients undergoing colectomy and appear to be enhanced in patients with chronic renal diseases. Chronic kidney diseases require dialysis is also a known surgical risk factor that in bowel resection increases the risk of death nearly 6-fold and doubles the complication rate. Therefore, some literature suggests laparoscopic surgery is not attempted for these patients considering their body habitus or longer operative time or creation of pneumoperitoneum which may be potentially associated with adverse pathophysiological changes, including hypercapnia, reduced venous return. However, in this study, patients with preoperative respiratory diseases and renal diseases benefit from laparoscopic surgery, which was consistent with previous reports. The reasons might be lower pain rate, less complication rate in laparoscopic surgery, and also it might be attributable to the enhanced post-operative recovery of lung function in laparoscopic group \[[@R23], [@R24]\]. Besides, a lung-protective PEEP during pneumoperitoneum might be also valuable for preventing intratidal recruitment/derecruitment \[[@R25]\].

Presently, better preoperative risk assessment should be introduced, objective and accurate evaluation of risk should become routine procedures, those would be helpful to predict and avoid postoperative complications by selecting the appropriate surgical approach. Cr-POSSUM model is a promising specialized tool for monitoring surgical outcomes in colorectal cancer surgery, which might be more accurate than P-POSSUM score \[[@R26], [@R27]\] in pre-operative use. In present research, patients suffering stage III/IV tumor with a laparoscopic surgery (60%) had primarily a significantly better outcome than patients undergoing open surgery (38.4%), as compared with DFS rates of 64.9% after laparoscopic surgery and 52.0% after open surgery among patients with stage III disease in the COREAN study. There was no significant difference in different Cr-POSSUM subgroups. Other study findings showed that elder patients might benefit most from improved short-term postoperative outcomes following the laparoscopic surgery \[[@R28]\]. Our research did not indicate significant improvements in the overall survival in different age group. The comparable survival rates were reported in series of literature. But the present study showed superior survival in laparoscopic resection, especially in stage III/IV cancers. We reviewed recent researchers: in 2010, the UK MRC CLASICC trial demonstrated that the 5-year overall survival rate (OSR) was 60.3% for laparoscopic rectal resection versus 52.9% for open surgery. Feliciotti´s group \[[@R29]\] (62.5%vs 60.6%), Ng et al \[[@R30]\] (63.9 %vs 55%), Law´s group \[[@R31]\] (71.1%vs 59.3%), Jayne et al \[[@R32]\] (60.3%vs 52.9%) and Baik et al \[[@R33]\] (90.8% vs 88.5%) all presented a better 5-year OSR for laparoscopic rectal resection, though the differences were not significant. Recently, it was reported that laparoscopic resection is associated with more favorable 5-year OS in stage II and III cancer \[[@R34], [@R35]\]. These results were not influenced by postoperative chemotherapy, which was given similarly after both approaches, especially for stage III cancer. The lower complication rate associated with laparoscopic resection might contribute to the better OS, this reason is more pronounced in the patients with high preoperative risk \[[@R36], [@R37], [@R38], [@R39]\]. Given the increased mortality and morbidity, all efforts should be made to medically optimize these patients preoperatively. One of the limitations of this study is the sample number, though the estimated power was 0.8 (α = 5%). For an instant, only a few patients with diabetes or cerebrovascular diseases were involved in the analyses which still need to be further improved under larger sample amount. Although a randomized controlled trial should be conducted to confirm the findings of the present study, the authors believe that the present study is of value in proposing the future studies.
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